{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-060232","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2026-05-13T20:06:07+00:00","discovered_at":"2026-05-13T20:07:00.323726+00:00","generated_at":"2026-05-13T20:08:32.035271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M","bullets":["Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.","Net loss narrowed to $2.2M ($0.08 loss per share) from $4.1M ($0.18 loss per share) YoY.","Adjusted EBITDA turned positive at $0.6M ($0.02 per share) vs negative $0.9M in Q1 2025.","Cash increased to $27M; gross margin 61% impacted by $1.3M non-cash API write-down.","SG&A down $0.5M to $10.1M due to lower Emrosi launch costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-060232","json":"https://secwatch.observer/filing/0001104659-26-060232.json","markdown":"https://secwatch.observer/filing/0001104659-26-060232.md","text":"https://secwatch.observer/filing/0001104659-26-060232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/0001104659-26-060232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465926060232/tm2614268d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T20:08:32.035271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}